Folarin O A, Gbotosho G O, Sowunmi A, Olorunsogo O O, Oduola A M J, Happi T C
Malaria Research Laboratories, Institute for Advanced Medical Research and Training (IMRAT), College of Medicine, University of Ibadan, Ibadan, Nigeria.
Open Trop Med J. 2008;1:74-82. doi: 10.2174/1874315300801010074.
This study was designed to evaluate the association between polymorphisms in pfcrt and pfmdr1 genes and in-vitro chloroquine (CQ) sensitivity in fresh isolates of P. falciparum and patients' treatment outcome. The modified schizont inhibition assay was used to determine in-vitro sensitivity of P. falciparum. Polymorphisms in pfcrt and pfmdr1 genes were detected using nested PCR and RFLP techniques in 84 P. falciparum isolates obtained from patients with acute uncomplicated malaria.Eighty five percent (71/84) and 15% (13/84) of the parasites were resistant and sensitive in-vitro to CQ respectively. Molecular analysis showed presence of mutant pfcrtT76, pfmdr1Y86 and pfmdr1F184 alleles in 60%, 33% and 14% of the isolates respectively. There was a significant association between in-vitro and in-vivo CQ resistance (p=0.029) and also between the presence of mutant pfcrtT76+pfmdr1 Y86-Y184 haplotype and in-vitro (p=0.013) or in-vivo CQ resistance (p=0.024).Overall results from this study demonstrates that the presence of pfcrtT76+ pfmdr1 Y86-Y184 haplotype in Nigerian isolates of Plasmodium falciparum is predictive of in-vitro and in-vivo CQ resistance and therefore may be useful for monitoring resistance to this drug.
本研究旨在评估恶性疟原虫新鲜分离株中pfcrt和pfmdr1基因多态性与体外氯喹(CQ)敏感性及患者治疗结果之间的关联。采用改良的裂殖体抑制试验来测定恶性疟原虫的体外敏感性。运用巢式PCR和RFLP技术,对从急性非复杂性疟疾患者中获得的84株恶性疟原虫分离株进行pfcrt和pfmdr1基因多态性检测。分别有85%(71/84)和15%(13/84)的疟原虫对CQ体外耐药和敏感。分子分析显示,分别有60%、33%和14%的分离株存在突变的pfcrtT76、pfmdr1Y86和pfmdr1F184等位基因。体外和体内CQ耐药之间存在显著关联(p = 0.029),突变的pfcrtT76 + pfmdr1 Y86 - Y184单倍型的存在与体外(p = 0.013)或体内CQ耐药之间也存在显著关联(p = 0.024)。本研究的总体结果表明,尼日利亚恶性疟原虫分离株中pfcrtT76 + pfmdr1 Y86 - Y184单倍型的存在可预测体外和体内CQ耐药,因此可能有助于监测对该药物的耐药性。